Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats

CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine

(2018) Heike Israel et al.   Current Pain and Headache Reports

CGRP as the target of new migraine therapies — successful translation from bench to clinic

(2018) Lars Edvinsson et al.   Nature Reviews Neurology

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention

(2018) Vladimir Skljarevski et al.   JAMA Neurology

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2017) Valery L Feigin et al.   LANCET NEUROLOGY

Stimulation of rat cranial dura mater with potassium chloride causes CGRP release into the cerebrospinal fluid and increases medullary blood flow

(2017) Mária Dux et al.   NEUROPEPTIDES

Pathophysiology of Migraine: A Disorder of Sensory Processing

(2017) Peter J. Goadsby et al.   PHYSIOLOGICAL REVIEWS

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

(2017) David Monteith et al.   Frontiers in Pharmacology

Ictal lack of binding to brain parenchyma suggests integrity of the blood–brain barrier for11C-dihydroergotamine during glyceryl trinitrate-induced migraine

(2016) Christoph J. Schankin et al.   BRAIN

Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics

(2016) Katherine L. Gill et al.   CLINICAL PHARMACOKINETICS

Lacosamide inhibits calcitonin gene-related peptide production and release at trigeminal level in the rat

(2016) M.C. Greco et al.   EUROPEAN JOURNAL OF PAIN

Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies

(2016) Silke Miller et al.   NEUROSCIENCE

Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood–brain barrier

(2015) Sajedeh Eftekhari et al.   BRAIN RESEARCH

Therapeutic antibodies against CGRP or its receptor

(2015) Marcelo E. Bigal et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment

(2015) Lars Edvinsson   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Experimental inflammation following dural application of complete Freund’s adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage

(2015) Cornelia Lundblad et al.   JOURNAL OF HEADACHE AND PAIN

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain

(2014) R.J. Benschop et al.   OSTEOARTHRITIS AND CARTILAGE

Pearls and pitfalls in neural CGRP immunohistochemistry

(2013) Karin Warfvinge et al.   CEPHALALGIA

Migraine: The seventh disabler

(2013) TJ Steiner et al.   CEPHALALGIA

The International Classification of Headache Disorders, 3rd edition (beta version)

(2013)   CEPHALALGIA

Brain Bioavailability of Human Intravenous Immunoglobulin and its Transport through the Murine Blood–Brain Barrier

(2013) Isabelle St-Amour et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice

(2012) Frédérique Bard et al.   EXPERIMENTAL NEUROLOGY

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

(2011) David J Hewitt et al.   CEPHALALGIA

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

(2008) Tony W Ho et al.   LANCET